WO2024051762 - ANTI-TROP2/EGFR ANTIBODIES AND USES THEREOF
National phase entry is expected:
Publication Number
WO/2024/051762
Publication Date
14.03.2024
International Application No.
PCT/CN2023/117376
International Filing Date
07.09.2023
Title **
[English]
ANTI-TROP2/EGFR ANTIBODIES AND USES THEREOF
[French]
ANTICORPS ANTI-TROP2/EGFR ET LEURS UTILISATIONS
Applicants **
XADCERA BIOPHARMACEUTICAL (SUZHOU) CO., LTD.
Room 301, Building C29, 218 Xinghu Street, Suzhou Industrial Park
Suzhou, Jiangsu 215127, CN
Inventors
LI, Zhuolin
No.12, Baoshen South Street, Daxing Bio-Medicine Industry Park
Daxing District, Beijing 102600, CN
GUAN, Xuewa
Room 301, Building C29, 218 Xinghu Street, Suzhou Industrial Park
Suzhou, Jiangsu 215127, CN
SHANG, Chengzhang
No.12, Baoshen South Street, Daxing Bio-Medicine Industry Park
Daxing District, Beijing 102600, CN
SHEN, Yuelei
No.12, Baoshen South Street, Daxing Bio-Medicine Industry Park
Daxing District, Beijing 102600, CN
Priority Data
PCT/CN2022/117496
07.09.2022
CN
PCT/CN2023/083228
23.03.2023
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
CNIPA
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 2498 | |
| EPO | Filing, Examination | 17845 | |
| Japan | Filing | 602 | |
| South Korea | Filing | 608 | |
| USA | Filing, Examination | 12685 |
Total: 34238 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The anti-TROP2/EGFR antibodies, and antibody drug conjugates derived therefrom, specifically bind to at least two different antigens EGFR and TROP2.[French]
L'invention concerne des anticorps anti-TROP2/EGFR et des conjugués anticorps-médicament dérivés de ceux-ci, qui se lient spécifiquement à au moins deux antigènes différents EGFR et TROP2.